Literature DB >> 22248992

Reduced brain natriuretic peptide levels in class III obesity: the role of metabolic and cardiovascular factors.

Alline Beleigoli1, Maria Diniz, Maria Nunes, Marcia Barbosa, Stephanie Fernandes, Mery Abreu, Antonio Ribeiro.   

Abstract

OBJECTIVE: Brain natriuretic peptide (BNP) has potent lipolytic action and, probably, a role in the biological mechanisms of obesity. Clinically, high levels are found in subjects with heart failure (HF). Low levels and inverse relation to BMI lead to questioning of its clinical utility in obese subjects, but heterogeneous results are found in severe obesity.
METHODS: In order to describe BNP behavior and its metabolic and cardiovascular determinants in class III obesity, we performed BNP measurement as well as clinical and echocardiographic evaluation of 89 subjects from two public hospitals in Brazil. Multivariate logistic ordinal regression with BNP tertiles as the dependent variable was performed.
RESULTS: Mean (± SD) age and BMI (± SD) was 44 ± 11.5 years and 53.2 ± 7.9 kg/m(2), respectively. 72 (81%) participants were women, and 18 (20%) had HF. Median BNP was 9.5 pg/ml(Q1 4.9; Q3 21.2 pg/ml). 30% of BNP values were below the detection limit of the method. In multivariate analysis, left atrial volume (LAV) was the only determinant of BNP levels (p 0.002) with odds-ratio of 1.1 (95% CI 1.03-1.16).
CONCLUSION: BNP levels are low in severe obesity, even in subjects with HF. LAV, which marks diastolic dysfunction, determines BNP levels, but not BMI and metabolic abnormalities.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22248992      PMCID: PMC6444748          DOI: 10.1159/000335174

Source DB:  PubMed          Journal:  Obes Facts        ISSN: 1662-4025            Impact factor:   3.942


  6 in total

1.  Association between the body mass index and the clinical findings in patients with acute heart failure: evaluation of the obesity paradox in patients with severely decompensated acute heart failure.

Authors:  Masato Matsushita; Akihiro Shirakabe; Noritake Hata; Takuro Shinada; Nobuaki Kobayashi; Kazunori Tomita; Masafumi Tsurumi; Hirotake Okazaki; Yoshiya Yamamoto; Kuniya Asai; Wataru Shimizu
Journal:  Heart Vessels       Date:  2016-10-24       Impact factor: 2.037

Review 2.  The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

Authors:  Angelo Avogaro; Gian Paolo Fadini
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

3.  Relation between E/e' ratio and NT-proBNP levels in elderly patients with symptomatic severe aortic stenosis.

Authors:  Mihai Strachinaru; Bas M van Dalen; Nicolas Van Mieghem; Peter P T De Jaegere; Tjebbe W Galema; Marielle Morissens; Marcel L Geleijnse
Journal:  Cardiovasc Ultrasound       Date:  2015-06-26       Impact factor: 2.062

4.  Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study.

Authors:  Taro Narumi; Tetsuro Shishido; Nobuyuki Kiribayashi; Shinpei Kadowaki; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Takehiko Miyashita; Takuya Miyamoto; Tetsu Watanabe; Yoko Shibata; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Exp Diabetes Res       Date:  2012-10-10

5.  The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function.

Authors:  Anne-Marie Gabrielsen; Torbjørn Omland; Mette Brokner; Jan Magnus Fredheim; Jens Jordan; Sverre Lehmann; May Brit Lund; Jøran Hjelmesæth; Dag Hofsø
Journal:  BMC Res Notes       Date:  2016-09-13

6.  Cardiac Hypertrophy and Brain Natriuretic Peptide Levels in an Ovariectomized Rat Model Fed a High-Fat Diet.

Authors:  Gleisy Kelly Goncalves; Thiago Henrique Caldeira de Oliveira; Najara de Oliveira Belo
Journal:  Med Sci Monit Basic Res       Date:  2017-12-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.